High performance of the BCR/ABL-extra sensitive (ES) probe for detection of der(9q) deletion in t(9;22) (q34;q11.2) [2]

Cancer Genetics and Cytogenetics

Volumn 132, Issue 2, 2002, Pages 171-

  Najfeld, Vesna ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME 9Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERPHASE; LETTER; PRIORITY JOURNAL; TECHNIQUE;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FUSION PROTEINS, BCR-ABL; HUMANS; MOLECULAR PROBES; TRANSLOCATION, GENETIC;

EID: 0037081846     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(01)00554-4     Document Type: Letter

References (4)

1. Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra cells
2. Improved sensitivity of BCR-ABL deletion; a triple-probe three-color flourescence in situ hybridization system
3. Large deletions at the t(9;22) breakpoint are common and may identify poor prognosis subgroup of patients with chronic myelogenous leukemia
4. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene; expression profiling, resistance to interferon therapy, and poor prognosis